We recently published 10 Stocks With Eye-Popping Double-Digit Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the ...

Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...

More than a third of Hims & Hers public float — over 65 million shares, or about 33.5% — are being sold short, according to data from Benzinga Pro . This level of short interest is well above average ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Telehealth platform Hims & Hers Health (NYSE:HIMS) shot to the top of stock charts yesterday as shares soared 16% high on no company news. While it is revolutionizing access to healthcare by ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and safety concerns.

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...